COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,704 Articles (22,913 medRxiv, 8,791 bioRxiv)

Most recent first Previous |  Page 1603: Articles 16021-16030  | Next

Preventing COVID-19 Outbreaks Through Surveillance Testing in Healthcare Facilities - A Modelling Study
Litwin, T., Timmer, J., Berger, M., Wahl-Kordon, A., Mueller, M., Kreutz, C.
10.1101/2021.05.03.21255976 — Posted: 2021-05-05
Optimal dose and safety of molnupiravir in patients with early SARS-CoV-2: a phase 1, dose-escalating, randomised controlled study
Khoo, S. H., FitzGerald, R., Fletcher, T., Ewings, S., Jaki, T., Lyon, R., Downs, N., Walker, L., Tansley-Hancock, O., Greenhalf, W., Woods, C., Reynolds, H., Marwood, E., Mozgunov, P., Adams, E., Bullock, K., Holman, W., Bula, M. D., Gibney, J. L., Saunders, G., Corkhill, A., Hale, C., Thorne, K., Chiong, J., Condie, S., Pertinez, H., Painter, W., Wrixon, E., Johnson, L., Yeats, S., Mallard, K., Radford, M., Fines, K., Shaw, V., Owen, A., Lalloo, D. G., Jacobs, M., Griffiths, G.
10.1101/2021.05.03.21256309 — Posted: 2021-05-05
Serological Response in Lung Transplant Recipients after Two Doses of SARS-CoV-2 mRNA Vaccines
Narasimhan, M., Mahimainathan, L., Clark, A. E., Usmani, A., Cao, J., Raj, E., Torres, F., Sarode, R., Kaza, V., Lacelle, C., Muthukumar, A.
10.1101/2021.04.26.21255926 — Posted: 2021-05-05
Within-host evolution of SARS-CoV-2 in an immunosuppressed COVID-19 patient: a source of immune escape variants
Weigang, S., Fuchs, J., Zimmer, G., Schnepf, D., Kern, L., Beer, J., Luxenburger, H., Ankerhold, J., Falcone, V., Kemming, J., Hofmann, M., Thimme, R., Neumann-Haefelin, C., Ulferts, S., Grosse, R., Hornuss, D., Tanriver, Y., Rieg, S., Wagner, D., Huzly, D., Schwemmle, M., Panning, M., Kochs, G.
10.1101/2021.04.30.21256244 — Posted: 2021-05-05
Does the Data Tell the True Story? A Modelling Study of Early COVID-19 Pandemic Suppression and Mitigation Strategies in Ghana
Frempong, N. K., Acheampong, T., Apenteng, O. O., Nakua, E., Amuasi, J. H.
10.1101/2021.05.02.21256473 — Posted: 2021-05-05
Lipid-Modulating Agents for Prevention or Treatment of COVID-19 in Randomized Trials
H. Talasaz, A. H., Sadeghipour, P., Aghakouchakzadeh, M., Dreyfus, I., Kakavand, H., Ariannejad, H., Gupta, A., Madhavan, M., Van tassell, B., Jimenez, D., Monreal, M., Vaduganathan, M., Fanikos, J., Dixon, D., Piazza, G., Parikh, S., Bhatt, D., Lip, G., Stone, G., Krumholz, H., Libby, P., Goldhaber, S., Bikdeli, B.
10.1101/2021.05.03.21256468 — Posted: 2021-05-05
Prevalence use of nonsteroidal anti-inflammatory drugs in the general population with COVID-19 and associated COVID-19 risk, hospitalization, severity, death, and safety outcomes: A systematic review and meta-analysis
zhao, h., huang, s., mei, k., shao, w., jiang, y., zhu, w., ma, j., zhang, j., yu, p., liu, x.
10.1101/2021.05.01.21256428 — Posted: 2021-05-05
Smart Testing with Vaccination: A Bandit Algorithm for Active Sampling for Managing COVID-19
Wang, Y., Yahav, I., Padmanabhan, B.
10.1101/2021.05.01.21256469 — Posted: 2021-05-05
SARS-CoV-2 Seroprevalence and Risk Factors among Convalescents in Sichuan Province, China: a retrospective cohort study
Zhou, L., Li, C., Yang, H., Yuan, H., Pan, M., Cheng, X., Su, X., Zhu, Y., Xu, J., Tang, J., Du, X., Peng, H., Xiao, C., Huang, T., Xian, D., Liao, H., Wang, H., Liu, W., Zhou, P., Zhang, Z., Liu, J., Wu, X., Zhang, T.
10.1101/2021.05.04.21256355 — Posted: 2021-05-05
LENZILUMAB EFFICACY AND SAFETY IN NEWLY HOSPITALIZED COVID-19 SUBJECTS: RESULTS FROM THE LIVE-AIR PHASE 3 RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED TRIAL
Temesgen, Z., Burger, C. D., Baker, J., Polk, C., Libertin, C., Kelley, C., Marconi, V. C., Orenstein, R., Durrant, C., Chappell, D., Ahmed, O., Chappell, G., Badley, A.
10.1101/2021.05.01.21256470 — Posted: 2021-05-05

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).